Virtual NR-565 Week 8 Final Advanced
Pharmacology Fundamentals 2026/ with
screenshots Questions and correct verified
answers. Guaranteed pass /Graded A+
,
,Comprehensive Topic Test | Questions | Latest 2026 Edition
SECTION A: DIABETES PHARMACOLOGY (Questions 1-25)
Question 1
Which of the following best explains why pioglitazone is ineffective in type 1
diabetes mellitus?
A) Lack of insulin sensitivity in peripheral tissues
B) Absence of endogenous insulin production
C) Activation of PPAR-γ receptors
D) Increased hepatic glucose production
<details> <summary><b>Correct Answer: B. Absence of endogenous insulin
production</b></summary>
Clinical Rationale: Pioglitazone is a thiazolidinedione (TZD) that acts as an insulin
sensitizer. Its mechanism requires the presence of endogenous insulin to enhance
peripheral glucose uptake. In type 1 diabetes, autoimmune destruction of
pancreatic beta cells results in absolute insulin deficiency, making insulin
sensitizers ineffective. The drug has no "target" to sensitize when insulin is
completely absent.
</details>
Question 2
A 52-year-old patient with type 2 diabetes and heart failure is being evaluated for
glucose-lowering therapy. Which medication should be AVOIDED in this patient?
A) Metformin
B) Pioglitazone
C) Sitagliptin
D) Insulin glargine
, <details> <summary><b>Correct Answer: B. Pioglitazone</b></summary>
Clinical Rationale: Thiazolidinediones (pioglitazone and rosiglitazone) cause fluid
retention and can precipitate or worsen heart failure. They are contraindicated in
patients with NYHA Class III or IV heart failure. Metformin is preferred as first-
line therapy unless contraindicated by renal impairment.
</details>
Question 3
A patient with type 2 diabetes is currently taking pioglitazone 30 mg daily. Which
laboratory value requires MOST careful monitoring?
A) Serum creatinine
B) Liver function tests (ALT, AST)
C) Hemoglobin A1c
D) Serum potassium
<details> <summary><b>Correct Answer: B. Liver function tests (ALT,
AST)</b></summary>
Clinical Rationale: Pioglitazone, like other TZDs, carries a risk of hepatotoxicity.
Baseline LFTs should be obtained and monitored periodically. While serum
creatinine is important for metformin, LFT monitoring is specifically indicated for
pioglitazone. The drug should be discontinued if ALT exceeds 2.5-3 times the
upper limit of normal.
</details>
Question 4
Which of the following is the primary mechanism of action for pioglitazone?
A) Increased insulin secretion from pancreatic beta cells
Pharmacology Fundamentals 2026/ with
screenshots Questions and correct verified
answers. Guaranteed pass /Graded A+
,
,Comprehensive Topic Test | Questions | Latest 2026 Edition
SECTION A: DIABETES PHARMACOLOGY (Questions 1-25)
Question 1
Which of the following best explains why pioglitazone is ineffective in type 1
diabetes mellitus?
A) Lack of insulin sensitivity in peripheral tissues
B) Absence of endogenous insulin production
C) Activation of PPAR-γ receptors
D) Increased hepatic glucose production
<details> <summary><b>Correct Answer: B. Absence of endogenous insulin
production</b></summary>
Clinical Rationale: Pioglitazone is a thiazolidinedione (TZD) that acts as an insulin
sensitizer. Its mechanism requires the presence of endogenous insulin to enhance
peripheral glucose uptake. In type 1 diabetes, autoimmune destruction of
pancreatic beta cells results in absolute insulin deficiency, making insulin
sensitizers ineffective. The drug has no "target" to sensitize when insulin is
completely absent.
</details>
Question 2
A 52-year-old patient with type 2 diabetes and heart failure is being evaluated for
glucose-lowering therapy. Which medication should be AVOIDED in this patient?
A) Metformin
B) Pioglitazone
C) Sitagliptin
D) Insulin glargine
, <details> <summary><b>Correct Answer: B. Pioglitazone</b></summary>
Clinical Rationale: Thiazolidinediones (pioglitazone and rosiglitazone) cause fluid
retention and can precipitate or worsen heart failure. They are contraindicated in
patients with NYHA Class III or IV heart failure. Metformin is preferred as first-
line therapy unless contraindicated by renal impairment.
</details>
Question 3
A patient with type 2 diabetes is currently taking pioglitazone 30 mg daily. Which
laboratory value requires MOST careful monitoring?
A) Serum creatinine
B) Liver function tests (ALT, AST)
C) Hemoglobin A1c
D) Serum potassium
<details> <summary><b>Correct Answer: B. Liver function tests (ALT,
AST)</b></summary>
Clinical Rationale: Pioglitazone, like other TZDs, carries a risk of hepatotoxicity.
Baseline LFTs should be obtained and monitored periodically. While serum
creatinine is important for metformin, LFT monitoring is specifically indicated for
pioglitazone. The drug should be discontinued if ALT exceeds 2.5-3 times the
upper limit of normal.
</details>
Question 4
Which of the following is the primary mechanism of action for pioglitazone?
A) Increased insulin secretion from pancreatic beta cells
